Show simple item record

dc.creatorRuberte, Ana Carolinaes_ES
dc.creatorGonzález Gaitano, Gustavoes_ES
dc.creatorSharma, Arun K.es_ES
dc.creatorAydillo, Carloses_ES
dc.creatorEncío Martínez, Ignacioes_ES
dc.creatorSanmartín, Carmenes_ES
dc.creatorPlano, Danieles_ES
dc.date.accessioned2021-06-14T11:17:34Z
dc.date.available2021-06-14T11:17:34Z
dc.date.issued2020
dc.identifier.issn0
dc.identifier.urihttps://hdl.handle.net/2454/39906
dc.descriptionIncluye material complementarioes_ES
dc.description.abstractAspirin (ASA) has attracted wide interest of numerous scientists worldwide thanks to its chemopreventive and chemotherapeutic effects, particularly in colorectal cancer (CRC). Incorporation of selenium (Se) atom into ASA has greatly increased their anti-tumoral efficacy in CRC compared with the organic counterparts without the Se functionality, such as the promising antitumoral methylseleno-ASA analog (1a). Nevertheless, the efficacy of compound 1a in cancer cells is compromised due to its poor solubility and volatile nature. Thus, 1a has been formulated with native α-, β-and γ-cyclodextrin (CD), a modified β-CD (hydroxypropyl β-CD, HP-β-CD) and Pluronic F127, all of them non-toxic, biodegradable and FDA approved. Water solubility of 1a is enhanced with β-and HP-β-CDs and Pluronic F127. Compound 1a forms inclusion complexes with the CDs and was incorporated in the hydrophobic core of the F127 micelles. Herein, we evaluated the cytotoxic potential of 1a, alone or formulated with β-and HP-β-CDs or Pluronic F127, against CRC cells. Remarkably, 1a formulations demonstrated more sustained antitumoral activity toward CRC cells. Hence, β-CD, HP-β-CD and Pluronic F127 might be excellent vehicles to improve pharmacological properties of organoselenium compounds with solubility issues and volatile nature.en
dc.description.sponsorshipC.S. and D.P. wish to express their gratitude to PIUNA (2018-19) and UNED-Pamplona, Fundación Bancaria La Caixa, and Fundación Caja Navarra for financial support for the project.en
dc.format.extent17 p.
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.publisherMDPIen
dc.relation.ispartofInternational Journal of Molecular Sciences, 2020, 21, 9017en
dc.rights© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAspirinen
dc.subjectColorectal canceren
dc.subjectCyclodextrinsen
dc.subjectCytotoxicityen
dc.subjectPluronicen
dc.subjectSeleniumen
dc.titleNew formulation of a methylseleno-aspirin analog with anticancer activity towards colon canceren
dc.typeinfo:eu-repo/semantics/articleen
dc.typeArtículo / Artikuluaes
dc.contributor.departmentUniversidad Pública de Navarra. Departamento de Ciencias de la Saludes_ES
dc.contributor.departmentNafarroako Unibertsitate Publikoa. Osasun Zientziak Sailaeu
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessen
dc.rights.accessRightsAcceso abierto / Sarbide irekiaes
dc.identifier.doi10.3390/ijms21239017
dc.relation.publisherversionhttps://doi.org/10.3390/ijms21239017
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.type.versionVersión publicada / Argitaratu den bertsioaes


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Except where otherwise noted, this item's license is described as © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.